Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance
Authors:
- Prasanna Srinivasan RamalingamPrasanna Srinivasan Ramalingam
- Manjunath Mirle RekhaMRManjunath Mirle Rekha
- Samir SahooSSSamir Sahoo
- Surya Nath PandeySPSurya Nath Pandey
- Chandana MajiCMChandana Maji
- Kavita GoyalKGKavita Goyal
- Haider AliHAHaider Ali
- Sachin Kumar SinghSSSachin Kumar Singh
- Gaurav GuptaGGGaurav Gupta
- Md. Sadique HussainMHMd. Sadique Hussain
- Purushothaman BalakrishnanPBPurushothaman Balakrishnan
Open Access
- 31 January 2026
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical AbstractKeywords
Funding Information
- Vellore Institute of Technology, Vellore
This publication has 168 references indexed in Scilit:
- Short‐chain acyl post‐translational modifications in cancers: Mechanisms, roles, and therapeutic implicationsCancer Communications, 2025
- USP7 promotes non‐small‐cell lung cancer cell glycolysis and survival by stabilizing and activating c‐AblClinical and Translational Medicine, 2023
- USP12 promotes nonsmall cell lung cancer progression through deubiquitinating and stabilizing RRM2Molecular Carcinogenesis, 2023
- The role of ubiquitin pathway‐mediated regulation of immune checkpoints in cancer immunotherapyCancer, 2023
- USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3KMolecular Oncology, 2022
- Ubiquitin-Regulated Cell Proliferation and Cancer2020
- Ubiquitin‐specific protease 44 inhibits cell growth by suppressing AKT signaling in non‐small cell lung cancerThe Kaohsiung Journal of Medical Sciences, 2019
- Ubiquitin specific peptidase 49 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signalingThe Kaohsiung Journal of Medical Sciences, 2019
- Tumors of the Respiratory Tract2016
- Well-Differentiated Malignancies2015